|
ENGLAND
Abingdon
 We
are a leader in the emerging field of proteomics, the comprehensive
study of proteins. We have successfully integrated proteomics with
genomics to create an innovative, proprietary drug discovery platform
that allows the systematic separation, identification and characterisation
of proteins on an industrial scale. Our goal is to use that platform
to enable the development of a new generation of break-through products
by: building a pipeline of proprietary small molecule and antibody
drug and diagnostic products based on a portfolio of patent applications
relating to, or to the use of, disease-associated proteins; and
providing proteomics services and data to the pharmaceutical and
life sciences industries.
|
Vertex's information-driven drug design approach combines diverse
technology disciplines and an integrated organizational philosophy
to increase the speed and success rate of drug discovery and development.
The information-driven drug design approach is dynamic-it has incorporated
and continues to integrate new technologies within the framework of
core biology, chemistry and biophysics disciplines. Vertex has developed
a variety of advanced and proprietary approaches, including compound
screening using NMR SHAPES, virtual screening using computer modeling
and combinatorial chemistry, and early incorporation of pharmacological
testing to drive the drug discovery process. By using these approaches,
as well as a range of available technologies, including use of x-ray
crystallography to determine the three-dimensional structure of a
drug target, Vertex has been able to accelerate drug discovery timelines
and increase success rates in early development compared to industry
averages. |
Cheshire
 A
global company focused on the advancement of all of the sciences supported
by mass spectrometry, with a commitment to finding new and more powerful
uses of MS technology wherever possible. Supplies the PROTEUM Series
of products which is focused on the determination of crystallographic
structures of proteins and other biological macromolecules. Don't
forget, Bruker
Daltonik Germany has a terrific website. |
Cambridge
 Astex
is a structure-based drug discovery company pioneering the use of
high throughput X-ray crystallography (HTX®) technology for the
rapid identification of novel drug candidates. HTX®Êtechnology
is part of an innovative drug discovery platform that integrates all
aspects of structure-based research, including protein production,
crystallization, structure determination, bioinformatics and computational
and medicinal chemistry. The discovery of novel drug leads at Astex
is driven by the company's unique structural screening approach that
utilizes protein crystal structures to discover and optimize lead
compounds. Astex's Pyramid™ approach to lead discovery utilizes
structural screening for the detection and optimization of small-molecule
fragments. Many thousands of these fragments are structurally screened
using the company's proprietary X-ray crystallography technologies.
This results in a powerful process for rapid structure-based lead
generation. Astex is using this approach to identify novel drug leads
for proprietary and public domain targets. |
 Drug
discovery is under increasing pressure to deliver increasing numbers
of development candidates to fill the corporate drug pipeline. This
means that there is an urgent need for high quality lead compounds
in order to drive the provision of candidates for pre-clinical development.
This problem is compounded by the ever-increasing number of putative
therapeutic targets coming out of Genomic and Proteomic research.
Our computational and medicinal chemists work closely together utilizing
our proprietary suite of programs in the design of novel scaffolds
that interact optimally with the chosen target binding sites. These
scaffolds are further elaborated with appropriate reagents inÊsilico,
to produce virtual combinatorial libraries that can be readily synthesised.
It is the close collaboration between Computational, Medicinal and
Combinatorial Chemists that makes this process so efficient. |
 Proteome
BioKnowledge® Library Now part of the Incyte family of products,
the Proteome BioKnowledge Library is a powerful collection of databases
focused on the compilation of available protein information. Using
our proprietary processes, we comb through relevant biological literature
for curation into our products. The data are then presented in an
easy to use format that offers enhanced flexibility and powerful time
savings over traditional library research. Access to thousands of
independent research results offers the competitive advantage of reduced
library research time and faster progression through discovery pathways.
|
 ProMetic
develops synthetic organic entities known as Mimetic Ligands™,
which are designed to effect very specific interactions with proteins.
Of particular interest is ProMetic's involvement in genomics, proteomics
and monoclonal antibodies where chemical ligands are used not only
to purify promising therapeutics, but can become lead compounds for
drug discovery programs as protein/peptide mimetic. To date, ProMetic
has developed and manufactured large scale Mimetic Ligands™ for
a wide range of therapeutics derived from plasma, recombinant or transgenic
sources. |
 Proteom
is a dedicated bioinformatics company which is defining the rules
that govern protein-protein interactions at the amino acid level -
the proteomic code. By coupling these rule sets with an understanding
of associated biology, Proteom is uniquely able to: design peptides
of around seven amino acids, predicted to bind with specific regions
of a protein; identify protein binding sites on a given protein; and
predict protein-protein interactions. Proteom's technology enables
the intelligent selection of targets and ligands in silico before
entering costly drug discovery programmes in the laboratory. |
 Accelrys
(formerly Molecular Simulations Inc.) delivers software and services
based on its industry-leading expertise in informatics and computation
for the biological, chemical, and materials sciences. The result is
the accelerated design, discovery, and development of pharmaceuticals,
chemicals, and materials. Accelrys meets these needs with an unrivalled
portfolio of technology, expertise developed through years of success
in developing and applying scientific software, a worldwide scientific
and sales presence, financial strength, and active partnerships with
major pharmaceutical, biotechnology, and chemical companies. Accelrys
is a subsidiary of Pharmacopeia Inc. |
 Sense
Proteomic Limited is a functional proteomics company that aims to
be a World leader in the development and use of protein-related molecular
technologies to enhance the productivity of the drug discovery process
and the efficacy of the therapies developed from it. These aims shall
be achieved through technology developments in collaboration with
pharmaceutical and biotechnology companies; the development, production
and marketing of functional protein arrays; and the discovery of novel
drug targets and leads through the application of its technologies.
Sense Proteomic was spun out from BritainÕs two oldest universities:
Oxford and Cambridge, being founded by Dr Roland Kozlowski and Dr
Jonathan Blackburn. The Company received its first round funding of
£3m in Autumn 2000 from Apax Partners & Co and is planning to raise
further capital in 2002 to further develop its technologies and products.
|
|
Proteome
Analysis Group at EBI
European
Bioinformatics Institute
Cambridge
Crystallographic Data Centre
|
Cambridgeshire
 NextGen
Sciences is a fast track technology development company specialising
in the fields of genomics, transcriptomics and proteomics. The company
integrates information at the level of the gene, gene transcript and
protein, developing technologies which include hardware, software
and the associated biochemistries to create, enhance and further facilitate
scientific and drug discovery knowledge and processes. The company's
business model is to generate early revenues through out-licensing
elements of their technology to key corporate partners who are well
renowned organisations with a global infrastructure in sales, marketing,
service and technical support. Recently, NextGen Sciences announced
their corporate partnership agreement with PerkinElmer Life Sciences
resulting in the introduction of the ProteinArray Workstation™,
the first fully automated system for processing protein microarrays,
which was developed using NextGen Sciences' derived intellectual property
and know-how. Under the terms of this agreement, PerkinElmer Life
Sciences will manufacture and have exclusive worldwide distribution
rights for the system. NextGen Science platform technologies are developed
by internally-driven research programmes, via collaboration and partnerships
with other companies and key academics with complementary skill sets.
|
Liverpool
Protein
Function Group (U of Liverpool) |
London
 Inpharmatica,
a leading informatics-driven drug discovery company, applies information
from its platform technologies on the relationships between the structure
and function of proteins to the discovery of novel drugs. |
|
Andrew
Miller Proteomics Group (Imperial College)
Biomolecular
Structure and Modelling Group (U College London)
Bloomsbury
Centre for Structure Biology (U College London)
Brunel
Bioinformatics Group (Brunel U)
School
of Crystallography (Birkbeck College)
Structure
and Modelling Group (U College London)
|
This site features Mascot, a powerful search engine which uses mass
spectrometry data to identify proteins from primary sequence databases.
To assist you, the help text for Mascot forms a substantial knowledge
base concerning protein identification by MS. |
|
Manchester
Michael
Barber Centre for Mass Spectrometry (UMIST)
Protein
Sequence Analysis Group (U of Manchester)
|
|
Newcastle
upon Tyne
 Established
in 1989, Nonlinear Dynamics is a leading worldwide provider of Bioinformatics
solutions to the life science industry. Our innovative product portfolio
comprises high-quality analysis and data mining tools for 1D and
2D electrophoresis gels and microarrays, the core technologies of
genomics and proteomics. Product Portfolio From high-volume, broad-based
projects to high-value, specialist studies, our products fulfil
scientific needs using leading-edge software tools. The Company
product range is built around the industry-standard Phoretix image
analysis and database software for 1D and 2D electrophoresis gels
and high-throughput arrays. A recent addition has been Progenesis,
a revolutionary product for the analysis of high-throughput 2D gels
used in major proteomics projects. Also in the pipeline is Progenera,
a product for the integration and in-depth interrogation of biodata
from proteomics and genomics studies, and Accelerator, a product
to extend the scalability of our software solutions. ISO 9001 /
TickIT accreditation gained in 1998 verifies and maintains the high
quality of design, development and production processes implemented
at Nonlinear.
|
Surrey
 Proteome
Sciences is a leading company in proteomics, a new scientific discipline
which enables correlations to be drawn between the range of proteins
produced by a cell or tissue, and the initiation or progression of
a disease state. Proteomic research permits the identification of
new protein markers for diagnostic purposes, and of novel molecular
targets for drug discovery. Proteome Sciences is applying its proprietary
proteomic technologies to identify novel protein markers of disease.
The levels of detection obtained achieve more than 10,000 times greater
sensitivity than existing methods. These discoveries will be further
developed and commercialised as diagnostic or therapeutic products
through external partnering arrangements. Proteome Sciences is headquartered
in Cobham, Surrey, UK, with research facilities located in London,
UK (at Harefield Hospital), and in Raleigh-Durham, North Carolina,
USA (at Intronn LLC, a US subsidiary). Proteome Sciences' research
capability is significantly expanded through exclusive collaboration
agreements with over 20 leading academic research establishments across
the world. This work has resulted in a large amount of useable data.
|
|
IRELAND
Irish
National Centre for BioInformatics
|
|
SCOTLAND
Aberdeen
 Biovation
is a UK-based biotechnology company using its proprietary DeImmunisation
technology to deliver a new generation of substantially non-immunogenic
therapeutic antibodies and proteins. Biovation works with its partners
in the biotechnology and pharmaceutical fields to eliminate immunogenicity
in a broad range of antibody and protein therapeutics through the
application of its groundbreaking DeImmunisation technology.Ê All
antibodies, even humanised and fully human, can potentially trigger
an immunogenic response when administered to patients.Ê DeImmunisation
of antibodies eliminates that risk without compromising efficacy.
|
| Aberdeen
Proteome Facility (University of Aberdeen) |
| |
| |
